MedSci Healthcare Holdings Ltd. Secures RMB21 Million Contract for Real-World Gout Study in China

Reuters

Sep 25

MedSci Healthcare Holdings Ltd. Secures RMB21 Million Contract for Real-World Gout Study in China

MedSci Healthcare Holdings Limited has announced that its subsidiary, Shanghai MedSci MedTech Co., Ltd., has been awarded a contract for a large-scale real-world study by a Chinese pharmaceutical company. The project, valued at approximately RMB 21 million, aims to systematically evaluate the efficacy and safety of IL-1β monoclonal antibody therapy in patients with acute and intercritical gout through a combined prospective and retrospective observational study. MedSci will utilize its internet-based physician platform, big data, and artificial intelligence technologies to support the project. The company stated that this initiative reflects its ongoing commitment to providing digital solutions for the healthcare sector.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedSci Healthcare Holdings Ltd. published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2570018566"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570018566\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570018566?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-25 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570018566","market":"fut","top_or_hot":-1,"title":"MedSci Healthcare Holdings Ltd. Secures RMB21 Million Contract for Real-World Gout Study in China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MedSci Healthcare Holdings Ltd. Secures RMB21 Million Contract for Real-World Gout Study in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MedSci Healthcare Holdings Limited has announced that its subsidiary, Shanghai MedSci MedTech Co., Ltd., has been awarded a contract for a large-scale real-world study by a Chinese pharmaceutical company. The project, valued at approximately RMB 21 million, aims to systematically evaluate the efficacy and safety of IL-1β monoclonal antibody therapy in patients with acute and intercritical gout through a combined prospective and retrospective observational study. MedSci will utilize its internet-based physician platform, big data, and artificial intelligence technologies to support the project. The company stated that this initiative reflects its ongoing commitment to providing digital solutions for the healthcare sector.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedSci Healthcare Holdings Ltd. published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MedSci Healthcare Holdings Ltd. Secures RMB21 Million Contract for Real-World Gout Study in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedSci Healthcare Holdings Ltd. Secures RMB21 Million Contract for Real-World Gout Study in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-25 21:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MedSci Healthcare Holdings Ltd. Secures RMB21 Million Contract for Real-World Gout Study in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MedSci Healthcare Holdings Limited has announced that its subsidiary, Shanghai MedSci MedTech Co., Ltd., has been awarded a contract for a large-scale real-world study by a Chinese pharmaceutical company. The project, valued at approximately RMB 21 million, aims to systematically evaluate the efficacy and safety of IL-1β monoclonal antibody therapy in patients with acute and intercritical gout through a combined prospective and retrospective observational study. MedSci will utilize its internet-based physician platform, big data, and artificial intelligence technologies to support the project. The company stated that this initiative reflects its ongoing commitment to providing digital solutions for the healthcare sector.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedSci Healthcare Holdings Ltd. published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1189","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDL1NyPQX:1","article_id":"2570018566","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570018566","pubTimestamp":1758806044,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MedSci Healthcare Holdings Limited has announced that its subsidiary, Shanghai MedSci MedTech Co., Ltd., has been awarded a contract for a large-scale real-world study by a Chinese pharmaceutical company. The project, valued at approximately RMB 21 million, aims to systematically evaluate the efficacy and safety of IL-1β monoclonal antibody therapy in patients with acute and intercritical gout through a combined prospective and retrospective observational study. MedSci will utilize its internet-based physician platform, big data, and artificial intelligence technologies to support the project. The company stated that this initiative reflects its ongoing commitment to providing digital solutions for the healthcare sector.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1189":"医疗保健技术","02415":"梅斯健康"},"translate_title":"MedSci Healthcare Holdings Ltd.获得人民币2100万元的中国痛风真实研究合同","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02415":0.9},"content_text":"MedSci Healthcare Holdings Ltd. Secures RMB21 Million Contract for Real-World Gout Study in China\n    \n\n        MedSci Healthcare Holdings Limited has announced that its subsidiary, Shanghai MedSci MedTech Co., Ltd., has been awarded a contract for a large-scale real-world study by a Chinese pharmaceutical company. The project, valued at approximately RMB 21 million, aims to systematically evaluate the efficacy and safety of IL-1β monoclonal antibody therapy in patients with acute and intercritical gout through a combined prospective and retrospective observational study. MedSci will utilize its internet-based physician platform, big data, and artificial intelligence technologies to support the project. The company stated that this initiative reflects its ongoing commitment to providing digital solutions for the healthcare sector.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedSci Healthcare Holdings Ltd. published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}